Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib

Brugioni, Emily; Cathcart-Rake, Elizabeth; Metsker, Janie; Gustafson, Elizabeth; Douglass, Lindsey; Pluard, Timothy

doi:10.1016/j.clbc.2023.04.006

Clinical Breast Cancer

2023

DOI: 10.1016/j.clbc.2023.04.006

|View full text |Cite

Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib

Emily Brugioni¹,

Elizabeth Cathcart-Rake

Janie Metsker

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing

Arun,

Couch,

Abraham

et al. 2024

Br J Cancer

View full text Add to dashboard Cite

Mutations in the BRCA1 and/or BRCA2 genes (BRCAm) increase the risk of developing breast cancer (BC) and are found in ~5% of unselected patients with the disease. BC resulting from a germline BRCAm (gBRCAm) has distinct clinical characteristics along with increased sensitivity to DNA-damaging agents such as poly(ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies, and potentially decreased sensitivity to cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Given the evolving treatment landscape for gBRCAm BC in early and advanced disease settings, timely determination of gBRCAm status is fundamental to facilitate the most effective treatment strategy for patients. However, many patients with gBRCAm are not identified due to suboptimal referral rates and/or a low uptake of genetic testing. We discuss current evidence for a differential response to treatment in patients with gBRCAm in early and advanced BC settings, including outcomes with PARP inhibitors, platinum-based chemotherapies, and CDK4/6 inhibitors, as well as ongoing treatment innovations and the potential of these treatment approaches. Current genetic testing strategies are also examined, including the latest guidelines on who and when to test for gBRCAm, as well as challenges to testing and how these may be overcome.

show abstract

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing

Arun,

Couch,

Abraham

et al. 2024

Br J Cancer

View full text Add to dashboard Cite

show abstract

Racial and socioeconomic disparities in triple-negative breast cancer treatment

Sarfraz,

Mehak

et al. 2024

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib

Cited by 2 publications

References 49 publications

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing

Racial and socioeconomic disparities in triple-negative breast cancer treatment

Contact Info

Product

Resources

About